AliceTsangShawMD

PubMed

• 5 citations
  Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations.
  Alessandra Bearz, Jean-François Martini, Jacek Jassem, Sang-We Kim, Gee-Chen Chang, Alice T Shaw, Deborah A Shepard, Elisa Dall'O', Anna Polli, Holger Thurm, Gerard Za...> ;Journal of Thoracic Oncology. 2023 Nov 1
• 17 citations
  Therapy-induced APOBEC3A drives evolution of persistent cancer cells.
  Hideko Isozaki, Ramin Sakhtemani, Ammal Abbasi, Naveed Nikpour, Marcello Stanzione, Sunwoo Oh, Adam Langenbucher, Susanna Monroe, Wenjia Su, Heidie Frisco Cabanos, Far...> ;Nature. 2023 Aug 1
• Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer.
  Benjamin J Solomon, Todd M Bauer, Tony S K Mok, Geoffrey Liu, Julien Mazieres, Filippo de Marinis, Yasushi Goto, Dong-Wan Kim, Yi-Long Wu, Jacek Jassem, Froylán López ...> ;Future Oncology. 2023 May 1
• 5 citations
  Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC.
  Ross A Soo, Jean-François Martini, Anthonie J van der Wekken, Shunsuke Teraoka, Roberto Ferrara, Alice T Shaw, Deborah Shepard, Anna Maria Calella, Anna Polli, Frances...> ;Journal of Thoracic Oncology. 2023 Nov 1
• 12 citations
  Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer.
  Arvind Ravi, Matthew D Hellmann, Monica B Arniella, Mark Holton, Samuel S Freeman, Vivek Naranbhai, Chip Stewart, Ignaty Leshchiner, Jaegil Kim, Yo Akiyama, Aaron T Gr...> ;Nature Genetics. 2023 May 1
• 24 citations
  ALK-positive lung cancer: a moving target.
  Jaime L Schneider, Jessica J Lin, Alice T Shaw> ;Nature Cancer. 2023 Mar 1
• 35 citations
  Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the ph...
  Benjamin J Solomon, Todd M Bauer, Tony S K Mok, Geoffrey Liu, Julien Mazieres, Filippo de Marinis, Yasushi Goto, Dong-Wan Kim, Yi-Long Wu, Jacek Jassem, Froylán López ...> ;The Lancet. Respiratory Medicine. 2023 Apr 1
• 10 citations
  Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer.
  Julien Mazieres, Laura Iadeluca, Alice T Shaw, Benjamin J Solomon, Todd M Bauer, Filippo de Marinis, Enriqueta Felip, Yasushi Goto, Dong-Wan Kim, Tony Mok, Arlene Reis...> ;Lung Cancer. 2022 Dec 1
• 3 citations
  A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on Crizotinib.
  Jaime L Schneider, Alona Muzikansky, Jessica J Lin, Elizabeth A Krueger, Inga T Lennes, Joseph O Jacobson, Michael Cheng, Rebecca S Heist, Zofia Piotrowska, Justin F G...> ;JTO Clinical and Research Reports. 2022 Jul 1
• Phase II Study of Cabozantinib in Patients With Bone Metastasis.
  Edwin Choy, Gregory M Cote, M Dror Michaelson, Lori Wirth, Justin F Gainor, Alona Muzikansky, Lecia V Sequist, Ryan J Sullivan, Panagiotis M Fidias, Alice Shaw, Rebecc...> ;The Oncologist. 2022 Jul 5
• 19 citations
  Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX Trial.
  Rafal Dziadziuszko, Solange Peters, Tony Mok, D Ross Camidge, Shirish M Gadgeel, Sai-Hong Ignatius Ou, Krzysztof Konopa, Johannes Noé, Malgorzata Nowicka, Walter Bordo...> ;Clinical Cancer Research. 2022 May 2
• 7 citations
  Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase-Positive Lung Cancer and CNS-Specific Relapse.
  Ibiayi Dagogo-Jack, Geoffrey R Oxnard, Makenzi Evangelist, Subba R Digumarthy, Jessica J Lin, Justin F Gainor, Michael S Rabin, Rebecca S Heist, Alona Muzikansky, Alic...> ;JCO Precision Oncology. 2022 May 1
• 7 citations
  Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease.
  Sai-Hong I Ou, Benjamin J Solomon, Alice T Shaw, Shirish M Gadgeel, Benjamin Besse, Ross A Soo, Antonello Abbattista, Francesca Toffalorio, Robin Wiltshire, Alessandra...> ;Journal of Thoracic Oncology. 2022 Apr 1
• 13 citations
  Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial.
  A S Mansfield, Z Wei, R Mehra, A T Shaw, C H Lieu, P M Forde, A E Drilon, E P Mitchell, J J Wright, N Takebe, E Sharon, D Hovelson, S Tomlins, J Zeng, K Poorman, N Mal...> ;NPJ Precision Oncology. 2022 Mar 1
• 4 citations
  Genetic landscape of patients with ALK-rearranged non–small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study
  D.S-W. Tan, Michael Thomas, D-W. Kim, Sebastian Szpakowski, Patrick Urban, Ranee Mehra, Laura Q.M. Chow, Sunil Sharma, Ben Solomon, Enriqueta Felip, D.R. Camidge, Joha...> ;Lung Cancer. 2021 Nov 20
• 84 citations
  Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms.
  Haichuan Hu, Zofia Piotrowska, Patricia J. Hare, Huidong Chen, Hillary E. Mulvey, Aislinn Mayfield, Sundus Noeen, Krystina E. Kattermann, Max Greenberg, August William...> ;Cancer Cell. 2021 Nov 8
• Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancer.
  Benjamin Solomon, Todd M. Bauer, Filippo de Marinis, Enriqueta Felip, Yasushi Goto, Geoffrey Liu, Julien Mazieres, Dong Wan Kim, Tony Mok, Anna Polli, Holger Thurm, A....> ;Future Oncology. 2021 Sep 29
• 47 citations
  Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion–Positive Lung Cancer
  Jessica J. Lin, Noura J. Choudhury, Satoshi Yoda, Viola W. Zhu, Ted William Johnson, Ramin Sakhtemani, Ibiayi Dagogo-Jack, Subba R. Digumarthy, Charlotte E. Lee, Andre...> ;Clinical Cancer Research. 2021 May 15
• 53 citations
  Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs.
  Enriqueta Felip, Alice T. Shaw, Alessandra Bearz, D.R. Camidge, Ben Solomon, Jessica Bauman, Todd M. Bauer, Solange Peters, F. Toffalorio, Antonello Abbattista, Holger...> ;Annals of Oncology. 2021 May 1
• 25 citations
  A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor.
  Ibiayi Dagogo-Jack, Philicia Moonsamy, Justin F. Gainor, Jochen K. Lennerz, Zofia Piotrowska, Jessica J. Lin, Inga T. Lennes, Lecia V. Sequist, Alice T. Shaw, Kelly Go...> ;Journal of Thoracic Oncology. 2021 May 1
• 4 citations
  Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the P...
  Tony Mok, Solange Peters, D. Ross Camidge, Johannes Noe, Shirish M. Gadgeel, Sai-Hong Ignatius Ou, Dong Wan Kim, Krzysztof Konopa, Emanuela Pozzi, Ting Liu, Isabell Lo...> ;Journal of Thoracic Oncology. 2021 Feb 1
• 24 citations
  Efficacy of Taletrectinib (AB-106/DS-6051b) in ROS1+ NSCLC: An Updated Pooled Analysis of U.S. and Japan Phase 1 Studies.
  Sai-Hong Ignatius Ou, Yutaka Fujiwara, Alice T. Shaw, Noboru Yamamoto, Kazuhiko Nakagawa, Frank Fan, Yuki Hao, Yanfei Gao, Pasi A. Jänne, Takashi Seto> ;JTO Clinical and Research Reports. 2021 Jan 1
• 435 citations
  First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
  Alice T. Shaw, Todd M. Bauer, Filippo de Marinis, Enriqueta Felip, Yasushi Goto, Geoffrey Liu, Julien Mazieres, Dong Wan Kim, Tony Mok, Anna Polli, Holger Thurm, A.M. ...> ;The New England Journal of Medicine. 2020 Nov 18
• 13 citations
  Association between circulating tumor DNA burden and disease burden in patients with ALK-positive lung cancer
  Eric W. Zhang, Ibiayi Dagogo-Jack, Anderson H. Kuo, Marguerite Rooney, Alice T. Shaw, Subba R. Digumarthy> ;Cancer. 2020 Oct 15
• 49 citations
  U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors.
  Kyriakos P. Papadopoulos, Erkut Borazanci, Alice T. Shaw, Ryohei Katayama, Yuki Shimizu, Viola W. Zhu, Thomas Yang Sun, Heather A. Wakelee, Russell Madison, Alexa B. S...> ;Clinical Cancer Research. 2020 Sep 15
• Join now to see all

Journal Articles

• Oxford University Press Has Registered This DOI Pre-Publication  
  R S Heist, Z Piotrowska, C G Azzoli, A T Shaw, I T Lennes, L V Sequist, J F Gainor, Oxford University Press
• Correlation of Extent of ALK FISH Positivity and Crizotinib Efficacy in Three Prospective Studies of ALK-Positive Patients with Non-Small Cell Lung Cancer  
  D R Camidge, A T Shaw, Annals of Oncology

Lectures

• Early circulating tumor (ct)DNA dynamics and efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC). 
  2019 ASCO Annual Meeting - 6/1/2019
• Avelumab (anti PD-L1) in combination with crizotinib or lorlatinib in patients with previously treated advanced NSCLC: Phase 1b results from JAVELIN Lung 101. Immunoth... 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
• Phase 3 Study of Crizotinib vs Pemetrexed or Docetaxel Chemotherapy in Patients with Advanced ALK+ NSCLC 
  2012 Congress, Vienna, Austria
• Phase 3 Study of Crizotinib vs Pemetrexed or Docetaxel Chemotherapy in Patients with Advanced ALK+ NSCLC 
  European Society for Medical Oncology, 2012 Congress, Vienna, Austria
• Join now to see all

Other

• Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer 
  Shaw AT, Solomon B
  http://www.uptodate.com/contents/anaplastic-lymphoma-kinase-alk-fusion-oncogene-positive-non-small-c
  UpToDate, Wolters Kluwer Health - 2013-04-09